The WHO Global Tuberculosis Report 2026, released on 12 November 2026, records a 38% fall in India's estimated TB mortality since 2015, from 28 to 18 deaths per lakh population in 2025. The global decline was 35%.
India's treatment success rate for drug-susceptible TB is 94%, and 96% of its TB programme funding comes from domestic resources.
Between 7 December 2024 and 8 November 2026, the TB Mukt Bharat Abhiyaan screened over 25 crore people and detected 48.64 lakh new cases, 14.97 lakh of them asymptomatic.
India and the world both remain well short of the End TB Strategy's 2025 milestone of a 75% cut in TB deaths.
India's national TB programme, renamed from the Revised National TB Control Programme (RNTCP) in 2020
Key: National target: end TB by 2025, five years ahead of the SDG deadline of 2030
Turn TB elimination into a people's movement (Jan Bhagidari)
Key: Launched by President Droupadi Murmu on 9 September 2022, along with the Ni-kshay Mitra initiative
Individuals, institutions and companies 'adopt' TB patients
Key: Provides extra nutritional, diagnostic and psychosocial support. It was later extended to patients' household contacts
Nutritional support to TB patients during treatment
Key: Started in April 2018 at Rs 500 a month via DBT. Doubled to Rs 1,000 a month in 2024
Bring youth into TB elimination
Key: Block- and ward-level teams led by a Class-I officer, each with five NCC cadets and five MY Bharat volunteers
Nucleic acid amplification tests detect TB bacteria's genetic material, which makes them faster and more sensitive than sputum microscopy. Truenat, from Goa-based Molbio Diagnostics, runs on a portable battery device, detects rifampicin resistance and was endorsed by WHO in July 2020.
Publishes the annual Global Tuberculosis Report and set the End TB Strategy targets
Began in 1956 as the Tuberculosis Chemotherapy Centre, was renamed the Tuberculosis Research Centre in 1970 and NIRT in 2011. It ran India's 2025 national TB prevalence survey
Runs the Sample Registration System, whose cause-of-death data fed WHO's 2026 estimate for India
Approved in September 2024 for multidrug-resistant TB. It combines bedaquiline, pretomanid and linezolid, with or without moxifloxacin, and cures in six months, against up to 20 months for older MDR-TB regimens
NTEP's digital platform for patient tracking and treatment monitoring. Its data was also one of the inputs to WHO's mortality estimate
GS Paper 2 > Social Justice > Health; GS Paper 3 > Science & Technology > Diseases
General Awareness > Reports and Indices > Health
General Awareness > Reports and Schemes
Share of notified TB patients who are cured or complete treatment; India's rate is 94% for drug-susceptible TB
Nucleic acid amplification test, a rapid molecular TB test (for example Truenat or CBNAAT)
TB with no symptoms, found only through active screening such as chest X-rays
TB resistant to at least isoniazid and rifampicin; BPaLM is its six-month regimen